Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr;41(4):1549-1561.
doi: 10.1007/s10792-021-01706-3. Epub 2021 Jan 22.

Teprotumumab (Tepezza): from the discovery and development of medicines to USFDA approval for active thyroid eye disease (TED) treatment

Faraat Ali  1 , Anushma Chorsiya  2 , Varisha Anjum  3 , Asad Ali  4
Affiliations
Review

Teprotumumab (Tepezza): from the discovery and development of medicines to USFDA approval for active thyroid eye disease (TED) treatment

Faraat Ali et al. Int Ophthalmol. 2021 Apr.

Abstract

Teprotumumab (TPT) is a type I insulin-like growth factor receptor inhibitor, marketed as Tepezza; recently USFDA approved it for the treatment of thyroid eye disease (thyroid-associated ophthalmopathy (TAO), Graves ophthalmopathy/orbitopathy) in the USA. It is a monoclonal antibody although it was initially developed in collaboration with Genmab and Roche for the treatment of the tumour, but later it was investigated by River Vision Development Corporation and Horizon Therapeutics for its ophthalmic use. The drug has been designated as an orphan drug, breakthrough designation and fast-track designation. This review summarizes the milestones in the research and development including ongoing, clinical trial of TPT till now, foremost to this primary approval for thyroid-associated ophthalmopathy (TAO).

Keywords: Graves disease; IGF-1R; R1507; RV001; Tepezza; Teprotumumab; Thyroid eye disease; Thyroid-associated ophthalmopathy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Wang Y, Smith TJ (2014) Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy. Invest Ophthalmol Vis Sci 55:1735–1748 - PubMed - PMC
    1. Bahn RS (2010) Graves’ ophthalmopathy. N Engl J Med 362(8):726–738 - PubMed - PMC
    1. Mellington FE, Dayan CM, Dickinson AJ et al (2017) Management of thyroid eye disease in the United Kingdom: a multicentre thyroid eye disease audit. Orbit 36:159–169 - PubMed
    1. Hodgson NM, Rajaii F (2020) Current understanding of the progression and management of thyroid associated orbitopathy: a systematic review. Ophthalmol Ther 9:21–33. https://doi.org/10.1007/s40123-019-00226-9 - DOI - PubMed
    1. Harris MA, Realini T, Hogg JP, Sivak-Callcott JA (2012) CT dimensions of the lacrimal gland in Graves orbitopathy. Ophthalmic Plast Reconstr Surg 28:69–72 - PubMed

MeSH terms

LinkOut - more resources